APOE genotype makes a small contribution to warfarin dose requirements
Elizabeth A Sconce1, Ann K Daly, Tayyaba I Khan
1School of Clinical and Laboratory Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.
Pharmacogenetics and Genomics
|July 19, 2006
Summary
Genetic variations in Apolipoprotein E (APOE) influence warfarin dosing. While APOE epsilon4 allele slightly affects warfarin dose, it is unlikely to be clinically significant for anticoagulation management.
Area of Science:
- Pharmacogenomics
- Clinical Biochemistry
Background:
- Vitamin K availability is crucial for warfarin anticoagulation efficacy.
- Apolipoprotein E (APOE) facilitates hepatic uptake of vitamin K.
- APOE gene polymorphisms may impact vitamin K metabolism and warfarin response.
Purpose of the Study:
- To investigate the association between common APOE gene polymorphisms (epsilon2, epsilon3, epsilon4) and warfarin dose requirements.
- To determine if APOE genotype influences the daily maintenance dose of warfarin in patients with stable anticoagulation.
Main Methods:
- Genotyping of APOE epsilon2, epsilon3, and epsilon4 alleles in patients with stable warfarin therapy (target INR 2.0-3.0).
- Comparison of mean daily warfarin doses across different APOE genotypes.
- Multivariate regression analysis incorporating age, height, CYP2C9, VKORC1, and APOE genotypes.
Main Results:
- Patients with at least one APOE epsilon4 allele required significantly lower mean daily warfarin doses compared to the epsilon3epsilon3 genotype (3.3 +/- 1.9 vs 4.0 +/- 1.8, P = 0.03).
- Multivariate analysis indicated that APOE epsilon4 allele significantly contributed to warfarin dose, though the effect was small (P = 0.002).
- No significant differences in fasted plasma vitamin K concentrations were observed between APOE genotypes.
Conclusions:
- The APOE epsilon4 allele shows a statistically significant, albeit small, association with reduced warfarin dose requirements.
- Despite statistical significance, the APOE genotype's contribution to warfarin dose variability is unlikely to be clinically significant.
- Further research may clarify the precise role of APOE in warfarin pharmacodynamics.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...